Which eye care claims create higher compliance risk in the USA (what should I avoid)?

Quick Answer (for busy buyers)

Here’s the buyer-first summary. If your brand name is on the label, you usually act as the responsible person and must ensure the listing is submitted and kept current.

• For US eye-care (Amazon/retail), highest-risk claims are those that imply treating or preventing a condition: “treats dry eye/blepharitis,” “anti-inflammatory,” “antibacterial,” “heals dermatitis/eczema,” “reduces eye bags permanently,” “repairs damaged capillaries,” “stimulates collagen/elastin,” or “promotes lash growth like a drug.” Also avoid “FDA approved/cleared,” “medical-grade,” and “clinically proven” unless you have proper studies you can produce on request.
• Safer territory is cosmetic language: “hydrates,” “helps reduce the appearance of dark circles/puffiness,” “smooths the look of fine lines,” “brightens,” “soothes,” and “supports the skin barrier,” backed by testing.
• We can support documentation and substantiation: COA/MSDS, ingredient review, stability + compatibility, preservative efficacy, microbiology, and optional ocular-irritation/HRIPT via third-party labs.
• Typical MOQ for eye products is 1,000-3,000 units/SKU depending on pack; sampling is ~7-14 days after brief confirmation; mass production lead time is usually ~25-35 days after sample sign-off and packaging readiness.
• We can advise on suitable eye-safe packaging (airless pump/tube), batch coding, and tamper-evidence.